[{"id":"7eb5032a-f810-48b6-80fe-022a794eb314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05029999","created_at":"2021-09-01T14:53:00.539Z","updated_at":"2024-07-02T16:34:26.023Z","phase":"Phase 1","brief_title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05029999","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • CDX-1140 • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 04/20/2025","primary_completion_date":" 04/20/2025","study_txt":" Completion: 04/20/2025","study_completion_date":" 04/20/2025","last_update_posted":"2024-06-14"},{"id":"e67b207c-524d-4340-9a2e-5cbef643f117","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616248","created_at":"2021-01-19T20:33:34.730Z","updated_at":"2024-07-02T16:35:26.987Z","phase":"Phase 1","brief_title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT04616248","lead_sponsor":"University of Southern California","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2023-12-06"},{"id":"12fc1d17-0a06-4691-bf0b-18767b9a6e88","acronym":"Mel66","url":"https://clinicaltrials.gov/study/NCT04364230","created_at":"2021-01-18T21:05:35.842Z","updated_at":"2024-07-02T16:35:33.934Z","phase":"Phase 1/2","brief_title":"Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)","source_id_and_acronym":"NCT04364230 - Mel66","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" BRAF • CD4 • FOXP3","pipe":"","alterations":" ","tags":["BRAF • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-10-11"}]